OncoC4, Inc. is a biotechnology company focused on developing innovative immunotherapies for hard-to-treat cancers and Alzheimer's disease. The company utilizes advanced scientific pathways involving immune checkpoints like CTLA-4, CD24, and Siglec to enhance the immune system's ability to identify and eliminate cancer cells. Their goal is to create safer and more effective therapies. The product pipeline includes a variety of therapeutic modalities such as monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and CAR T-cell therapies. These treatments are designed to tackle the complexities of cancer and neurodegenerative diseases by targeting both innate and adaptive immune checkpoints. Founded by leading immunologists, OncoC4 is supported by a team with extensive experience in clinical development and business strategy. The company is headquartered in Rockville, Maryland, and is dedicated to advancing its clinical pipeline through research partnerships and investor collaborations.
We're tracking OncoC4, Inc.'s market expansion
How OncoC4, Inc.'s international expansion compares to its competitors
OncoC4, Inc.YouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 OncoC4, Inc.You | 0 | 0 | — | 0 | 0 |
Not hiring right now
Sign up to track this company and get alerted the moment something changes.
No active campaigns
Sign up to track this company and get alerted the moment something changes.
BioNTech and OncoC4's Gotistobart shows over 50% reduction in mortality risk compared to chemotherapy in lung cancer patients, with potential as a chemo-free monotherapy.
OncoC4 dosed first participant in Phase 1/2 trial of ONC-841 for Alzheimer's disease at Xuanwu Hospital, China, following NMPA clearance. ONC-841 is world's first anti-SIGLEC 10 antibody.
OncoC4 announced NMPA's Breakthrough Therapy Designation for gotistobart to treat squamous non-small cell lung cancer, expediting its development and review in China.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about OncoC4, Inc.'s business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
